The Million Hearts initiative, which aims to prevent a million cardiovascular events in a 5-year period, will focus on utilizing its partnerships with health systems and employers as it embarks upon its second phase, according to Janet Wright, MD, FACC, the program’s executive director.
The Million Hearts initiative, which aims to prevent a million cardiovascular events in a 5-year period, will focus on utilizing its partnerships with health systems and employers as it embarks upon its second phase, according to Janet Wright, MD, FACC, the program’s executive director.
Transcript (slightly modified)
What’s on the horizon for the Million Hearts initiative in the coming years?
What we’re excited about in Million Hearts 2022 is first and foremost that all of the partnerships and relationships that were either formed or deepened in the first 5 years are geared up and ready to go. In fact, their wheels are all turning. So we believe that although we likely will not have prevented a million events in the first 5 years, we are setting that aim again for the second 5 years, and we believe that the partnerships and many different types of relationships are the ticket to getting there.
In addition, there are some policies that started out in late 2011 and early 2012 that were conceptual, but now are actually pervasive across the country. So more and more places are basing their payment on value, and that allows performance of a whole team of people, really getting away from the fee-for-service model. And in addition, we have a number of best practices and lessons learned that we can layer on top of the existing evidence to make sure that improvements occur quickly.
Frankly, all 50 states have been involved in Million Hearts, including the District of Columbia, as well as many health systems. We will be looking to hospitals and academic medical centers as major partners in 2022, as well as employers who care deeply about the health of their employees.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More